



INDO-BANGLA PHARMACEUTICALS PLC.

Corporate Office:

Plot-183 (7th Floor), Block # B, Ahmed Akbar Sobhan Road,
Bashundhara R/A, Dhaka-1229.

Factory: 729, College Road, Barishal-8200.

PRICE SENSITIVE INFORMATION

This is for kind information that, the Board of Directors of Indo-Bangla Pharmaceuticals PLC (“Company”) in its meeting held on Thursday 30th April, 2026 at 4:00 p.m. at the corporate office, has approved the Un-Audited Financial Statements for the Third Quarter (Q3) period ended on 31th March, 2026.

The key financial highlights for the Third Quarter ended 31th March, 2026 are appended below:

SL No.	Particulars	9 months		3 months	
		July to March		January to March	
		2025-2026	2024-2025	2025-2026	2024-2025
1.	Earnings Per Share (EPS)	0.02	(0.17)	0.01	(0.09)
2.	Net Operating Cash Flows Per Share (NOCFPS)	0.01	0.02	-	-
		As at 31 st March, 2026		As at 30 th June, 2025	
3.	Net Asset Value (NAV) per share	12.56		12.53	

The reasons, for significant deviation:

- **Sales revenue** increased by 75.29% for the nine months and 95.59% for the third quarter compared to the same periods of the previous year, mainly due to higher sales volume driven by improved market demand, expanded distribution coverage, and better market penetration.
- **Earnings Per Share (EPS)** improved due to higher revenue, improved gross profit, and better control over operating expenses during the period.
- **Net Operating Cash Flow per Share (NOCFPS)** decreased due to higher working capital requirements and increased operating cash payments in line with higher business activity.
- **Net Asset Value (NAV)** per share per share slightly increased due to profit earned during the period.

By order of the Board of Directors

-sd-

(Md. Mohi Uddin)

Company Secretary